SG11201408292YA - Dry powder for inhalation formulation comprising salmeterol xinafoate, fluticasone propionate and tiotropium bromide, and method for preparing same - Google Patents
Dry powder for inhalation formulation comprising salmeterol xinafoate, fluticasone propionate and tiotropium bromide, and method for preparing sameInfo
- Publication number
- SG11201408292YA SG11201408292YA SG11201408292YA SG11201408292YA SG11201408292YA SG 11201408292Y A SG11201408292Y A SG 11201408292YA SG 11201408292Y A SG11201408292Y A SG 11201408292YA SG 11201408292Y A SG11201408292Y A SG 11201408292YA SG 11201408292Y A SG11201408292Y A SG 11201408292YA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- gyeonggi
- inhalation formulation
- dry powder
- suwon
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 19 December 2013 (19.12.2013) WIPOIPCT (10) International Publication Number WO 2013/187626 A1 (51) International Patent Classification: A61K 9/14 (2006.01) A61K31/56 (2006.01) A61K9/16 (2006.01) A61K31/166 (2006.01) (21) International Application Number: (22) International Filing Date: (25) Filing Language: (26) Publication Language: PCT/KR2013/004880 3 June 2013 (03.06.2013) English English (30) Priority Data: 10-2012-0063665 14 June 2012 (14.06.2012) KR (71) Applicant: HANMI PHARM. CO., LTD. [KR/KR]; #893-5, Hajeo-ri, Paltan-myeon, Hwaseong-si, Gyeong- gi-do 445-910 (KR). (72) Inventors: KIM, Kyeong Soo; 113-1902, 85, Hwasan-ro, Jangan-gu, Suwon-si, Gyeonggi-do 440-710 (KR). LEE, Deokkyu; 1222-402, 50, Mokdongdong-ro, Yangcheon- gu, Seoul 158-772 (KR). KIM, Dong Ho; 809-ho, 12, Seongnam-daero 172beon-gil, Bundang-gu, Seongnam-si, Gyeonggi-do 463-853 (KR). KIM, Yong II; 147-2201, 57, Hwasan-ro, Paldal-gu, Suwon-si, Gyeonggi-do 442-872 (KR). PARK, Jae Hyun; 311-404, 460, Yeongtong-ro, Yeongtong-gu, Suwon-si, Gyeonggi-do 443-737 (KR). WOO, Jong Soo; 120-2303, 85, Hwasan-ro, Jangan-gu, Suwon-si, Gyeonggi-do 440-330 (KR). (74) Agent: FIRSTLAW P.C.; Trust Tower, 275-5, Yang- jae-Dong, Seocho-Ku, Seoul 137-739 (KR). (81) Designated States (unless otherwise indicated, for every kind of national protection available)'. AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available)'. ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) (54) Title: DRY POWDER FOR INHALATION FORMULATION COMPRISING SALMETEROL XINAFOATE, FLUTIC ASONE PROPIONATE AND TIOTROPIUM BROMIDE, AND METHOD FOR PREPARING SAME Aerodynamic size distribution salmeterol of CJ i> 00 i-H en i-H o CJ o & O) m o & C0 M— o E 3 CO El Example 1 Example 1 (Handyhaler®) • 10 Urnim • 30 L/mim Z2 60 L/mim Ofl 90 L/mim Example 5 Comp. Ex. 2 Comp. Ex. 3 (57) Abstract: Provided is a dry powder for inhalation formulation comprising salmeterol xinafoate, fluticasone propionate and tio - tropium bromide, as pharmaceutically active ingredients, and a carrier, and an inhalation formulation comprising same. The invent - ive dry powder inhalation formulation having good content uniformity and showing small changes in the aerodynamic size distribu - tion in accordance with the flow rate changes can effectively deliver said pharmaceutically active ingredients to a target site upon ad - ministration, and thus can be useful in the prevention or treatment of respiratory diseases, particularly asthma and COPD.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020120063665A KR20130140358A (en) | 2012-06-14 | 2012-06-14 | Dry powder for inhalation formulation comprising salmeterol xinafoate, fluticasone propionate and tiotropium bromide, and method for preparing the same |
PCT/KR2013/004880 WO2013187626A1 (en) | 2012-06-14 | 2013-06-03 | Dry powder for inhalation formulation comprising salmeterol xinafoate, fluticasone propionate and tiotropium bromide, and method for preparing same |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201408292YA true SG11201408292YA (en) | 2015-01-29 |
Family
ID=49758405
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201408292YA SG11201408292YA (en) | 2012-06-14 | 2013-06-03 | Dry powder for inhalation formulation comprising salmeterol xinafoate, fluticasone propionate and tiotropium bromide, and method for preparing same |
Country Status (19)
Country | Link |
---|---|
US (2) | US9283232B2 (en) |
EP (1) | EP2861219A4 (en) |
JP (1) | JP2015519394A (en) |
KR (1) | KR20130140358A (en) |
CN (1) | CN104363895A (en) |
AU (1) | AU2013275113A1 (en) |
BR (1) | BR112014030910A2 (en) |
CA (1) | CA2876283A1 (en) |
HK (1) | HK1206602A1 (en) |
IL (1) | IL236198A0 (en) |
IN (1) | IN2014DN11257A (en) |
MX (1) | MX2014014755A (en) |
NZ (1) | NZ703788A (en) |
PH (1) | PH12014502746A1 (en) |
RU (1) | RU2015100905A (en) |
SG (1) | SG11201408292YA (en) |
TW (1) | TWI565481B (en) |
WO (1) | WO2013187626A1 (en) |
ZA (1) | ZA201500208B (en) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112016030972B1 (en) | 2014-06-30 | 2020-12-15 | Proveris Scientific Corporation | SAMPLING APPLIANCE FOR DETERMINING THE QUANTITY AND UNIFORMITY OF A DOSE OF MEDICINAL PRODUCT PROVIDED AND RELATED METHODS |
KR20160038767A (en) * | 2014-09-30 | 2016-04-07 | 한미약품 주식회사 | Dry powder for inhalation formulation with improved stability of combined active ingredients |
MA41378A (en) * | 2015-01-20 | 2017-11-28 | Teva Branded Pharmaceutical Prod R & D Inc | DRY POWDER INHALER CONSISTING OF FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE |
KR20160117069A (en) | 2015-03-31 | 2016-10-10 | 한미약품 주식회사 | Capsule for inhalation with improved stability of combined active ingredients |
WO2016178704A1 (en) * | 2015-05-01 | 2016-11-10 | Board Of Regents, The University Of Texas System | Multidrug brittle matrix compositions |
EP3426329A4 (en) * | 2016-03-09 | 2019-11-13 | Proveris Scientific Corporation | Methods for measuring dose content uniformity performance of inhaler and nasal devices |
CN108066329B (en) * | 2016-11-11 | 2021-11-16 | 江苏恒瑞医药股份有限公司 | Preparation method of microparticles of fluticasone or derivatives thereof for inhalation |
KR102330428B1 (en) * | 2019-10-14 | 2021-11-24 | 한미약품 주식회사 | Dry powder for inhalation formulation and preparation method thereof |
AU2021296221A1 (en) * | 2020-06-26 | 2023-02-02 | Mylan Pharma Uk Limited | Formulations including 5-(3-(3-hydroxyphenoxy)azetidin-1-yl)-5-methyl-2,2-diphenylhexanamide |
CN115266987B (en) * | 2022-07-31 | 2023-06-30 | 浙江知一药业有限责任公司 | Pharmaceutical composition for treating respiratory diseases |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9322014D0 (en) | 1993-10-26 | 1993-12-15 | Co Ordinated Drug Dev | Improvements in and relating to carrier particles for use in dry powder inhalers |
GB0003935D0 (en) * | 2000-02-08 | 2000-04-12 | King S College London | Formulation for dry powder inhaler |
DE10130371A1 (en) | 2001-06-23 | 2003-01-02 | Boehringer Ingelheim Pharma | New drug compositions based on anticholinergics, corticosteroids and betamimetics |
GB0312148D0 (en) | 2003-05-28 | 2003-07-02 | Aventis Pharma Ltd | Stabilized pharmaceutical products |
SE527190C2 (en) * | 2003-06-19 | 2006-01-17 | Microdrug Ag | Administration of metered dry powder combined doses of finely divided dry medication powders involves selecting first and second medicaments for forming of pharmaceutical, combined doses |
GB0326632D0 (en) | 2003-11-14 | 2003-12-17 | Jagotec Ag | Dry powder formulations |
EP2124915A2 (en) * | 2007-02-19 | 2009-12-02 | Cipla Limited | Pharmaceutical combinations of at least two bronchodilators or of a bronchodilator with a corticosteroid |
EP2197444A1 (en) | 2007-09-12 | 2010-06-23 | Glaxo Group Limited | Novel combination of therapeutic agents |
US9637840B2 (en) | 2008-07-18 | 2017-05-02 | Prosonix Limited | Process for improving crystallinity |
EP2328556A4 (en) * | 2008-07-30 | 2013-11-20 | Stc Unm | Formulations containing large-size carrier particles for dry powder inhalation aerosols |
TR201000681A2 (en) | 2010-01-29 | 2011-08-22 | B�Lg�� Mahmut | Dry powder formulations inhaled. |
-
2012
- 2012-06-14 KR KR1020120063665A patent/KR20130140358A/en not_active Application Discontinuation
-
2013
- 2013-06-03 US US14/402,548 patent/US9283232B2/en not_active Expired - Fee Related
- 2013-06-03 MX MX2014014755A patent/MX2014014755A/en unknown
- 2013-06-03 CA CA2876283A patent/CA2876283A1/en not_active Abandoned
- 2013-06-03 JP JP2015517171A patent/JP2015519394A/en active Pending
- 2013-06-03 BR BR112014030910A patent/BR112014030910A2/en not_active IP Right Cessation
- 2013-06-03 EP EP13804439.1A patent/EP2861219A4/en not_active Withdrawn
- 2013-06-03 CN CN201380030898.0A patent/CN104363895A/en active Pending
- 2013-06-03 SG SG11201408292YA patent/SG11201408292YA/en unknown
- 2013-06-03 RU RU2015100905A patent/RU2015100905A/en not_active Application Discontinuation
- 2013-06-03 IN IN11257DEN2014 patent/IN2014DN11257A/en unknown
- 2013-06-03 WO PCT/KR2013/004880 patent/WO2013187626A1/en active Application Filing
- 2013-06-03 AU AU2013275113A patent/AU2013275113A1/en not_active Abandoned
- 2013-06-03 NZ NZ703788A patent/NZ703788A/en not_active IP Right Cessation
- 2013-06-13 TW TW102120909A patent/TWI565481B/en not_active IP Right Cessation
-
2014
- 2014-12-09 PH PH12014502746A patent/PH12014502746A1/en unknown
- 2014-12-11 IL IL236198A patent/IL236198A0/en unknown
-
2015
- 2015-01-13 ZA ZA2015/00208A patent/ZA201500208B/en unknown
- 2015-06-22 US US14/746,225 patent/US9549936B2/en not_active Expired - Fee Related
- 2015-07-27 HK HK15107131.8A patent/HK1206602A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2013187626A1 (en) | 2013-12-19 |
CA2876283A1 (en) | 2013-12-19 |
PH12014502746B1 (en) | 2015-02-02 |
TWI565481B (en) | 2017-01-11 |
US9549936B2 (en) | 2017-01-24 |
RU2015100905A (en) | 2016-08-10 |
TW201402154A (en) | 2014-01-16 |
BR112014030910A2 (en) | 2017-06-27 |
AU2013275113A1 (en) | 2015-02-05 |
US20150283151A1 (en) | 2015-10-08 |
HK1206602A1 (en) | 2016-01-15 |
US9283232B2 (en) | 2016-03-15 |
IN2014DN11257A (en) | 2015-10-09 |
ZA201500208B (en) | 2016-10-26 |
PH12014502746A1 (en) | 2015-02-02 |
EP2861219A4 (en) | 2015-10-28 |
NZ703788A (en) | 2016-10-28 |
KR20130140358A (en) | 2013-12-24 |
JP2015519394A (en) | 2015-07-09 |
IL236198A0 (en) | 2015-01-29 |
US20150157566A1 (en) | 2015-06-11 |
CN104363895A (en) | 2015-02-18 |
MX2014014755A (en) | 2015-02-24 |
EP2861219A1 (en) | 2015-04-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201408292YA (en) | Dry powder for inhalation formulation comprising salmeterol xinafoate, fluticasone propionate and tiotropium bromide, and method for preparing same | |
SG11201903514VA (en) | Novel cd47 monoclonal antibodies and uses thereof | |
SG11201809132RA (en) | Novel compounds as autotaxin inhibitors and pharmaceutical compositions comprising the same | |
SG11201808990QA (en) | Compositions for topical application of compounds | |
SG11201805120YA (en) | Zika virus vaccine | |
SG11201804811WA (en) | Fenfluramine compositions and methods of preparing the same | |
SG11201805072PA (en) | Nicotine powder delivery system | |
SG11201909963YA (en) | Methods for treating dravet syndrome | |
SG11201407397WA (en) | Formulations and methods for vaginal delivery of antiprogestins | |
SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
SG11201810628XA (en) | Nasal pharmaceutical compositions with a porous excipient | |
SG11201407340YA (en) | Treatment of myelosuppression | |
SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
SG11201407228PA (en) | N-aryltriazole compounds as lpar antagonists | |
SG11201408251SA (en) | A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota | |
SG11201809908TA (en) | Stabilized glycopeptide antibiotic formulations | |
SG11201804048WA (en) | A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic | |
SG11201806868TA (en) | Compositions and methods for protecting against airborne pathogens and irritants | |
SG11201805001UA (en) | Method of treating influenza a | |
SG11201804050QA (en) | A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic | |
SG11201402986RA (en) | Kinase inhibitors | |
SG11201407110QA (en) | Novel dosage form and formulation of abediterol | |
SG11201408240TA (en) | Treatment of motor and movement disorder side effects associated with parkinson's disease treatments | |
SG11201408273TA (en) | Time synchronizing of distinct video and data feeds that are delivered in a single mobile ip data network compatible stream | |
SG11201407536UA (en) | Topical pharmaceutical compositions comprising terbinafine and urea |